Monogram Orthopaedics, Inc. (MGRM) Stock Analysis
DELISTED 2025
What happened to Monogram Orthopaedics, Inc. (MGRM) stock?
Monogram Orthopaedics, Inc. (MGRM) no longer trades on public markets. It was delisted in October 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Monogram Orthopaedics, Inc. (MGRM) trades at $6.00. Monogram Orthopaedics, Inc. is a medical device company focused on personalized orthopedic implants and robotic surgical equipment. The company aims to revolutionize joint replacement procedures through mass-personalized optimization. Market cap: $244M, Sector: Healthcare.
Last analyzed: Jun 1, 2026MGRM stock analysis for 2026: Analysts have set a consensus price target of $5.40 for Monogram Orthopaedics, Inc., suggesting 10.0% downside from the current price of $6.00. Key factors: analyst coverage, company fundamentals.
MGRM: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Monogram Orthopaedics, Inc. (MGRM) Healthcare & Pipeline Overview
Monogram Orthopaedics is a healthcare company developing robotic surgical equipment and personalized orthopedic implants, aiming to improve precision and outcomes in joint replacement. Their focus on mass-personalized optimization differentiates them in the competitive medical device market, targeting a significant unmet need for tailored surgical solutions.
What Is the Investment Thesis for MGRM?
Monogram Orthopaedics presents a compelling, albeit high-risk, investment opportunity within the orthopedic device market. The company's focus on personalized implants and robotic-assisted surgery addresses a growing demand for improved precision and patient-specific solutions. The potential for enhanced surgical outcomes and reduced revision rates could drive significant adoption of Monogram's technology. However, the company's negative profit margin of -3027.0% and gross margin of -10.4% highlight the challenges of commercializing novel medical technologies. Key catalysts include successful completion of clinical trials and regulatory approvals. The company's small size and limited resources pose risks, but successful execution could yield substantial returns. The beta of 0.69 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
MGRM Key Highlights
Market capitalization of $244M reflects investor expectations for future growth in the personalized orthopedic implant market.
- Negative profit margin of -3027.0% indicates significant investment in R&D and commercialization efforts, typical for early-stage medical device companies.
- Gross margin of -10.4% suggests that the cost of goods sold currently exceeds revenue, highlighting the need for efficient manufacturing and pricing strategies.
- Beta of 0.69 indicates lower volatility compared to the broader market, potentially appealing to risk-averse investors.
- The company's focus on robotic-assisted surgery and personalized implants positions it to capitalize on the growing demand for precision medicine in orthopedics.
Who Are MGRM's Competitors?
MGRM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings, Inc. | $100.72 | -0.02% | $19.5B | 78 |
| SYK Stryker Corporation | $340.11 | +0.04% | $131B | 79 |
| PROF Profound Medical Corp. | $7.08 | +1.14% | $257M | 67 |
| ANIK Anika Therapeutics, Inc. | $21.34 | +0.38% | $286M | 84 |
| BSGM BioSig Technologies, Inc. | $6.10 | +37.08% | $191M | 61 |
| DMTRF 3-D Matrix, Ltd. | $2.50 | +0.00% | $320M | 66 |
| VMD Viemed Healthcare, Inc. | $8.57 | -4.14% | $326M | 87 |
| ELMD Electromed, Inc. | $40.00 | -2.13% | $331M | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MGRM's Key Strengths?
Innovative robotic surgical platform.
- Focus on personalized orthopedic implants.
- Potential for improved surgical outcomes.
- Strong intellectual property portfolio.
What Are MGRM's Weaknesses?
Limited commercialization experience.
- Negative profit and gross margins.
- Small company size and resources.
- Dependence on regulatory approvals.
What Could Drive MGRM Stock Higher?
Completion of clinical trials for Monogram's robotic surgical system.
- FDA clearance for Monogram's personalized knee implant.
- Expansion of Monogram's intellectual property portfolio.
- Strategic partnerships with leading hospitals and surgical centers.
What Are the Key Risks for MGRM?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Delays in regulatory approvals for Monogram's products.
- Competition from established orthopedic device companies.
- Negative profit and gross margins impacting financial sustainability.
- Dependence on securing additional funding for R&D and commercialization.
What Are the Growth Opportunities for MGRM?
- Expansion into New Orthopedic Applications: Monogram Orthopaedics can leverage its robotic surgery platform and personalized implant technology to expand into other orthopedic applications beyond knee and hip replacements. This includes addressing shoulder, elbow, and ankle joint replacements, representing a significant market opportunity. The global market for shoulder and elbow replacements alone is projected to reach $2.5 billion by 2030, providing a substantial growth avenue for Monogram.
- Strategic Partnerships with Hospitals and Surgical Centers: Collaborating with leading hospitals and surgical centers to integrate Monogram's technology into their orthopedic programs can accelerate adoption and market penetration. These partnerships can provide access to a broader patient base, facilitate clinical trials, and establish Monogram as a preferred provider of personalized orthopedic solutions. Successful partnerships could lead to increased revenue and brand recognition within the medical community.
- Development of Advanced Software and AI Capabilities: Enhancing the software and AI components of Monogram's robotic surgery platform can further improve surgical precision, efficiency, and patient outcomes. This includes developing advanced algorithms for pre-operative planning, real-time surgical guidance, and post-operative monitoring. The integration of AI can also enable predictive analytics to optimize implant design and surgical techniques, creating a competitive advantage for Monogram.
- Geographic Expansion into International Markets: Expanding into international markets, such as Europe and Asia, can significantly increase Monogram's revenue potential. These markets have a growing demand for advanced orthopedic solutions and represent a substantial opportunity for Monogram to establish a global presence. However, international expansion requires navigating regulatory hurdles, adapting products to local market needs, and establishing distribution networks.
- Securing Additional Funding and Investment: Securing additional funding through venture capital, strategic partnerships, or public offerings is crucial for Monogram to support its R&D efforts, clinical trials, and commercialization activities. Adequate funding will enable the company to accelerate the development and launch of its products, expand its sales and marketing efforts, and strengthen its competitive position in the orthopedic device market. The ability to attract and secure funding is essential for Monogram's long-term growth and success.
What Threats Does MGRM Face?
- Competition from established orthopedic device companies.
- Regulatory hurdles and delays.
- Technological obsolescence.
- Economic downturn impacting healthcare spending.
What Are MGRM's Competitive Advantages?
- Proprietary robotic surgical technology.
- Personalized implant design capabilities.
- Patents protecting key innovations.
- First-mover advantage in mass-personalized orthopedics.
What Does MGRM Do?
Monogram Orthopaedics, Inc., incorporated in 2016 and headquartered in Austin, Texas, is dedicated to transforming orthopedic surgery through personalized implants and robotic technology. Originally named Monogram Arthroplasty Inc., the company rebranded in March 2017 to reflect its broader focus on orthopedic solutions. The company is developing a comprehensive product architecture designed to enable mass personalization of orthopedic implants, addressing the unique anatomical needs of each patient. Their core offering includes robotic surgical equipment, related software, orthopedic implants, tissue ablation tools, navigation consumables, and other instrumentation necessary for reconstructive joint replacement procedures. Monogram's robot prototype is engineered to execute precise paths for the insertion of optimized implants into synthetic bone specimens. This technology aims to enhance surgical accuracy and improve implant fit, potentially leading to better patient outcomes and reduced revision rates. The company's approach seeks to move beyond standard, one-size-fits-all implants by creating solutions tailored to individual patient anatomy. By integrating robotics and personalized implant design, Monogram Orthopaedics aims to set a new standard in orthopedic care, offering surgeons advanced tools and patients more effective and durable joint replacements. The company currently has 27 employees.
What Products and Services Does MGRM Offer?
- Develop robotic surgical equipment for orthopedic procedures.
- Design and manufacture personalized orthopedic implants.
- Create software for surgical planning and navigation.
- Produce tissue ablation tools for joint replacement.
- Offer navigation consumables for precise implant placement.
- Provide instrumentation for reconstructive joint replacement procedures.
How Does MGRM Make Money?
- Sales of robotic surgical equipment to hospitals and surgical centers.
- Revenue from the sale of personalized orthopedic implants.
- Recurring revenue from software licenses and updates.
- Sales of navigation consumables used in surgical procedures.
What Industry Does MGRM Operate In?
The medical device industry is experiencing a shift towards personalized medicine and robotic-assisted surgery. The orthopedic implant market is projected to grow, driven by an aging population and increasing demand for joint replacement procedures. Monogram Orthopaedics is positioned to capitalize on these trends with its focus on personalized implants and robotic technology. However, the company faces competition from established players in the orthopedic device market, such as Zimmer Biomet and Stryker, who have greater resources and market share.
Who Are MGRM's Key Customers?
- Hospitals and medical centers performing orthopedic surgeries.
- Orthopedic surgeons specializing in joint replacement procedures.
- Patients requiring joint replacement or reconstructive surgery.
Financial Health
Monogram Orthopaedics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 12.64 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on assets is -85.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.0%, the inverse of the P/E and a quick read on earnings relative to price.
Monogram Orthopaedics, Inc. (MGRM) Valuation Context
Valued at $244M, MGRM is classified as a micro-cap stock.
Forward Outlook
Wall Street analysts project Monogram Orthopaedics, Inc. revenue of about $13.4M for fiscal 2026, with EPS near $-0.08.
MGRM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Monogram Orthopaedics has seen recent insider buying, suggesting confidence from those closest to the company. This is a positive signal, especially in a market where insider selling is more common.
- The community seems optimistic about MGRM's potential to disrupt the orthopedics market with its personalized implants. This narrative is gaining traction.
- There's a growing belief that MGRM's technology could lead to better patient outcomes, which resonates well with socially conscious investors.
- The company’s focus on a niche market (personalized orthopedic implants) could provide a competitive advantage over larger players, similar to how smaller biotech firms sometimes outperform big pharma in specific disease areas.
Bear Case
- Despite the optimism, MGRM is still in the early stages of commercialization. Scaling up production and distribution could present significant challenges.
- Community sentiment can be fickle. Positive buzz doesn't always translate to long-term success, as seen with many meme stocks that have faded.
- The orthopedics market is dominated by established players with deep pockets. MGRM will face intense competition for market share.
- The regulatory pathway for personalized implants could be lengthy and uncertain, potentially delaying market entry and increasing costs. Think of the challenges faced by companies developing novel medical devices.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MGRM Latest News
No recent news available for MGRM.
Leadership: Benjamin Sexson
CEO
Benjamin Sexson serves as the Chief Executive Officer of Monogram Orthopaedics, Inc. His background includes extensive experience in the medical device industry, with a focus on product development and commercialization. He has a proven track record of leading teams and driving innovation in the orthopedic space. Sexson's expertise spans across engineering, marketing, and business strategy, making him well-suited to guide Monogram Orthopaedics through its growth phase. He is responsible for overseeing all aspects of the company's operations, from research and development to sales and marketing.
Track Record: Under Benjamin Sexson's leadership, Monogram Orthopaedics has focused on advancing its robotic surgical platform and personalized implant technology. He has overseen the development of the company's robot prototype and the expansion of its intellectual property portfolio. Sexson has also been instrumental in securing funding for the company's R&D efforts and establishing strategic partnerships with key stakeholders in the orthopedic industry. His strategic decisions have positioned Monogram Orthopaedics as a leader in personalized orthopedic solutions.
What Investors Ask About Monogram Orthopaedics, Inc. (MGRM) — Healthcare
What happened to Monogram Orthopaedics, Inc. (MGRM) stock?
Monogram Orthopaedics, Inc. (MGRM) no longer trades on public markets. It was delisted in October 2025. The figures below are historical and are not a current quote.
Can I still buy MGRM shares?
No. MGRM stopped trading on public markets in October 2025, so the shares are not available through a broker. Anything you see quoted for MGRM elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MGRM stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Monogram Orthopaedics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Monogram Orthopaedics, Inc. do?
Monogram Orthopaedics, Inc. is a medical device company focused on revolutionizing joint replacement surgery through personalized implants and robotic-assisted technology. They are developing a robotic surgical system and patient-specific implants designed to improve surgical precision, implant fit, and patient outcomes.
What do analysts say about MGRM stock?
Analyst coverage of Monogram Orthopaedics (MGRM) is limited, reflecting its small-cap status and early stage of development. Key valuation metrics are difficult to assess due to the company's negative profit margins and limited revenue. However, analysts recognize the potential of Monogram's personalized implant and robotic surgery technology to disrupt the orthopedic device market.
What are the main risks for MGRM?
Monogram Orthopaedics faces several key risks, including regulatory hurdles, competition, and financial sustainability. The company's success depends on obtaining FDA clearance for its robotic surgical system and personalized implants, which can be a lengthy and uncertain process. Monogram also competes with established orthopedic device companies that have greater resources and market share.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent filings.